...
首页> 外文期刊>ACS Omega >Analysis of Biphenyl-Type Inhibitors Targeting the Eg5 α4/α6 Allosteric Pocket
【24h】

Analysis of Biphenyl-Type Inhibitors Targeting the Eg5 α4/α6 Allosteric Pocket

机译:针对Eg5α4/α6变构口袋的联苯型抑制剂的分析

获取原文

摘要

Eg5 is a mitotic kinesin protein that plays an important role in the formation and maintenance of the bipolar spindle during the mitotic phase. Due to its potentially reduced side effects in cancer therapy, Eg5 is considered to be an attractive target for developing anticancer inhibitors. Herein, we report a computational modeling study involving biphenyl-type inhibitors known to interact with the α4/α6 allosteric pocket of Eg5. Compared to the well-known α2/L5/α3 allosteric inhibitors, biphenyl-type inhibitors show a unique activity profile. In the Eg5–PVZB1194 (a biphenyl-type inhibitor) crystal structure, loop L11, which is located in the entrance of the α4/α6 allosteric-binding pocket, is missing due to crystal-packing effects. To better understand the role of this flexible loop upon biphenyl-type inhibitor-binding, MD simulations were performed to observe the L11 conformations from different states. It was demonstrated that L11 was more stabilized and showed less fluctuation when PVZB1194 was bound to Eg5. Residue Asn287 from L11 forms hydrogen bonding to the sulfone group of PVZB1194, whereby L11 moves inward to the α4/α6 allosteric pocket and moves away from the pocket in absence of the inhibitor. Pharmacophore, three-dimensional (3D)-QSAR, and ADME studies of biphenyl-type inhibitors of Eg5 were also performed. A best pharmacophore model, DDRRH.6, was generated, having correlation coefficients in the 3D-QSAR study of R ~(2) = 0.81 and Q ~(2) = 0.64. Furthermore, docking studies were carried out to observe the interaction between the remaining biphenyl-type inhibitors with Eg5. In addition, on the basis of fragment docking, a structure-based pharmacophore was generated, which shares good overlap of the DHRR features of the pharmacophore model DDHRR.6. The structure-based pharmacophore also contains extra hydrogen-bond acceptors and hydrophobic groups, features which provide possibilities in developing new or improved series of compounds.
机译:Eg5是一种有丝分裂驱动蛋白,在有丝分裂期的双极纺锤体的形成和维持中起着重要作用。由于其在癌症治疗中的潜在副作用减少,Eg5被认为是开发抗癌抑制剂的诱人靶标。在这里,我们报告了一个计算模型研究,涉及与Eg5的α4/α6变构口袋相互作用的联苯型抑制剂。与众所周知的α2/ L5 /α3变构抑制剂相比,联苯型抑制剂表现出独特的活性。在Eg5-PVZB1194(一种联苯型抑制剂)的晶体结构中,由于晶体堆积效应,位于α4/α6变构结合口袋入口处的环L11消失了。为了更好地了解该柔性环对联苯型抑制剂结合的作用,进行了MD模拟以观察来自不同状态的L11构象。结果表明,当PVZB1194与Eg5结合时,L11更稳定,波动较小。来自L11的残基Asn287与PVZB1194的砜基形成氢键,由此L11向内移动至α4/α6变构口袋,并在没有抑制剂的情况下从口袋移开。还进行了对Eg5联苯型抑制剂的药理学,三维(3D)-QSAR和ADME研究。生成了最佳药效团模型DDRRH.6,在3D-QSAR研究中,相关系数为R〜(2)= 0.81和Q〜(2)= 0.64。此外,进行对接研究以观察剩余的联苯型抑制剂与Eg5之间的相互作用。此外,基于片段对接,生成了基于结构的药效基团,该结构与药效基团模型DDHRR.6的DHRR特征具有良好的重叠。基于结构的药效团还包含额外的氢键受体和疏水基团,这些特征为开发新的或改良的系列化合物提供了可能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号